Nerea Sainz-Pastor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nerea Sainz-Pastor has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Adela Pozo Giráldez
Servicio de Bioquímica Clínica y Patología Molecular, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
2 shared publications - Adrián Bravo Gómez
Servicio de Bioquímica Clínica, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
2 shared publications - Anita Dayaldasani Khialani
Comisión de Estrés Oxidativo, Sociedad Española de Medicina de Laboratorio (SEMEDLAB), 08025 Barcelona, Spain
2 shared publications - Isabel Fort-Gallifa
Facultat de Medicina i Ciències de la Salut, University Rovira i Virgili, 43003 Tarragona, Spain
2 shared publications - Paula Sienes Bailo
Servicio de Bioquímica Clínica, Hospital Universitario Miguel Servet, Zaragoza, España
2 shared publications - Pilar Calmarza
Comisión de Estrés Oxidativo, Sociedad Española de Medicina de Laboratorio (SEMEDLAB), 08025 Barcelona, Spain
2 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (6) , 1350-1363
Implementation of an Automated Lipoprotein(a) Assay on a Third-Party Automated Analyzer: Validation, Method Comparison, and Clinical Impact of Formula-Based Mass-to-Molar Conversion
Background: Lipoprotein(a) [Lp(a)] is an independent, genetically determined cardiovascular risk factor. Although consensus recommends reporting Lp(a) in molar units using assays with minimized apolipoprotein(a) [apo(a)] isoform size–related bias, some laboratories still use mass units with conversion formulas of uncertain reliability. This study describes the first adaptation and validation of the Roche Tina-quant® Lp(a) Gen.2 assay [TQ-Lp(a)] on the Atellica Solution platform, including method comparison and evaluation of formula-based mass-to-molar conversion. Methods: A total of 126 serum samples were analyzed using 3 approaches: Roche TQ-Lp(a) as the molar comparator method, adapted Atellica-TQ-Lp(a), and native Siemens Lp(a) on Atellica CH, which reports results in mg/dL. Siemens mass-based results were converted to nmol/L using the manufacturer’s equation. Analytical performance was assessed according to Spanish Society of Laboratory Medicine recommendations. Method comparison included Passing–Bablok regression, Bland–Altman, and Cohen κ at clinically relevant thresholds. Results: Atellica-TQ-Lp(a) demonstrated acceptable precision (CV <6%), excellent linearity (r = 0.99), and adequate sensitivity (limit of quantification, 8 nmol/L). No relevant interference was observed, and stability was maintained for 4 days under refrigerated and frozen conditions. Agreement with the comparator method was high (slope, 0.99; intercept, 3.9 nmol/L; r = 0.99), with minimal constant bias and high categorical concordance (weighted κ = 0.98). In contrast, formula-derived values showed proportional bias (slope, 1.27), moderate agreement (weighted κ = 0.78), and frequent upward reclassification at ≥125 nmol/L. Conclusions: The Roche Tina-quant® Lp(a) Gen.2 assay can be implemented on Atellica CH to report Lp(a) in nmol/L with high analytical comparability to the Roche/cobas implementation. Fixed mg/dL-to-nmol/L conversion formulas introduce systematic bias and clinically relevant misclassification.
- 19 August 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (6) , 1350-1363
Open AccessImplementation of an Automated Lipoprotein(a) Assay on a Third-Party Automated Analyzer: Validation, Method Comparison, and Clinical Impact of Formula-Based Mass-to-Molar Conversion
Background: Lipoprotein(a) [Lp(a)] is an independent, genetically determined cardiovascular risk factor. Although consensus recommends reporting Lp(a) in molar units using assays with minimized apolipoprotein(a) [apo(a)] isoform size–related bias, some laboratories still use mass units with conversion formulas of uncertain reliability. This study describes the first adaptation and validation of the Roche Tina-quant® Lp(a) Gen.2 assay [TQ-Lp(a)] on the Atellica Solution platform, including method comparison and evaluation of formula-based mass-to-molar conversion. Methods: A total of 126 serum samples were analyzed using 3 approaches: Roche TQ-Lp(a) as the molar comparator method, adapted Atellica-TQ-Lp(a), and native Siemens Lp(a) on Atellica CH, which reports results in mg/dL. Siemens mass-based results were converted to nmol/L using the manufacturer’s equation. Analytical performance was assessed according to Spanish Society of Laboratory Medicine recommendations. Method comparison included Passing–Bablok regression, Bland–Altman, and Cohen κ at clinically relevant thresholds. Results: Atellica-TQ-Lp(a) demonstrated acceptable precision (CV <6%), excellent linearity (r = 0.99), and adequate sensitivity (limit of quantification, 8 nmol/L). No relevant interference was observed, and stability was maintained for 4 days under refrigerated and frozen conditions. Agreement with the comparator method was high (slope, 0.99; intercept, 3.9 nmol/L; r = 0.99), with minimal constant bias and high categorical concordance (weighted κ = 0.98). In contrast, formula-derived values showed proportional bias (slope, 1.27), moderate agreement (weighted κ = 0.78), and frequent upward reclassification at ≥125 nmol/L. Conclusions: The Roche Tina-quant® Lp(a) Gen.2 assay can be implemented on Atellica CH to report Lp(a) in nmol/L with high analytical comparability to the Roche/cobas implementation. Fixed mg/dL-to-nmol/L conversion formulas introduce systematic bias and clinically relevant misclassification.
- 27 June 2026
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 86 (5) , 1-9
Challenges in the interpretation of amphetamine results: differences of reactivity between immunoassay and immunochromatography
Urine drug screening is a valuable diagnostic tool for assessing acute intoxications in the emergency department. Enzyme immunoassay (IA) and immunochromatography (IC) are the two main techniques routinely used due to their rapid turnaround, low cost, and high sensitivity. However, results must be interpreted with caution, as structural cross-reactivity may cause false-positive (FP) findings. We retrospectively analyzed 55 urine samples from emergency patients initially screened for amphetamines by IA and confirmed by gas chromatography-mass spectrometry (GC-MS). Samples containing amphetamine derivatives or potentially cross-reactive substances (tetracaine, trazodone, methylphenidate, ritalinic acid, phentermine, procainamide, ephedrine, bisoprolol, and synthetic cathinones) were subsequently analyzed using an IC assay. Diagnostic performance and cross-reactivity were compared between both screening methods. Of the 55 samples selected by IA, 34 were true positives (TP), 8 true negatives (TN), 2 false negatives (FN), and 11 FP. FP by IA were mainly due to tetracaine, trazodone, phentermine, ephedrine, and procainamide. In comparison, IC yielded 32 TP, 17 TN, 2 FP (phentermine and bisoprolol), and 4 FN. No cross-reactivity with methylphenidate and synthetic cathinones was observed in either technique. IC showed frequent misclassifications between amphetamine and methamphetamine while MDMA detection was more specific. IC is a reliable and rapid alternative for amphetamine screening in the emergency setting, providing improved specificity and fewer false positives than IA. Given its limited discrimination between amphetamine and methamphetamine, IC results should be reported as 'amphetamine derivatives'. These findings highlight assay-dependent cross-reactivity and the importance of understanding methodological limitations for an accurate interpretation.
- 27 June 2026
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 86 (5) , 1-9
Challenges in the interpretation of amphetamine results: differences of reactivity between immunoassay and immunochromatography
Urine drug screening is a valuable diagnostic tool for assessing acute intoxications in the emergency department. Enzyme immunoassay (IA) and immunochromatography (IC) are the two main techniques routinely used due to their rapid turnaround, low cost, and high sensitivity. However, results must be interpreted with caution, as structural cross-reactivity may cause false-positive (FP) findings. We retrospectively analyzed 55 urine samples from emergency patients initially screened for amphetamines by IA and confirmed by gas chromatography-mass spectrometry (GC-MS). Samples containing amphetamine derivatives or potentially cross-reactive substances (tetracaine, trazodone, methylphenidate, ritalinic acid, phentermine, procainamide, ephedrine, bisoprolol, and synthetic cathinones) were subsequently analyzed using an IC assay. Diagnostic performance and cross-reactivity were compared between both screening methods. Of the 55 samples selected by IA, 34 were true positives (TP), 8 true negatives (TN), 2 false negatives (FN), and 11 FP. FP by IA were mainly due to tetracaine, trazodone, phentermine, ephedrine, and procainamide. In comparison, IC yielded 32 TP, 17 TN, 2 FP (phentermine and bisoprolol), and 4 FN. No cross-reactivity with methylphenidate and synthetic cathinones was observed in either technique. IC showed frequent misclassifications between amphetamine and methamphetamine while MDMA detection was more specific. IC is a reliable and rapid alternative for amphetamine screening in the emergency setting, providing improved specificity and fewer false positives than IA. Given its limited discrimination between amphetamine and methamphetamine, IC results should be reported as 'amphetamine derivatives'. These findings highlight assay-dependent cross-reactivity and the importance of understanding methodological limitations for an accurate interpretation.
- Top Cited PapersOpen Access
- 21 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 1075
Oxidative Stress and Its Role in Vascular Damage and Atherosclerosis
Oxidative stress (OS) resulting from an imbalance between reactive oxygen species (ROS) generation and antioxidant defenses plays a pivotal role in vascular diseases such as atherosclerosis and hypertension. ROS derived from NADPH oxidase, mitochondria, and xanthine oxidase promote endothelial dysfunction by inducing lipid and protein oxidation, apoptosis, and pro-inflammatory signaling, thereby enhancing smooth muscle proliferation and atherogenesis. This review summarizes the molecular mechanisms linking OS to vascular injury and aims to systematically elucidate the role of OS in vascular diseases, with a specific focus on critiquing the current challenges in translating biomarkers to clinical practice and the emerging trends in personalized antioxidant therapy. Particular attention is given to biomarkers of oxidative stress, including those assessing antioxidant enzyme activity and oxidative damage products, which possess potential for clinical use. Therapeutic strategies targeting OS, including dietary and pharmacological antioxidants, show promise in improving vascular health, although clinical outcomes have been inconsistent and it is necessary to resolve the standardization and validation of these biomarkers, develop precise targeted therapies against specific ROS sources (e.g., NOX inhibitors, mitochondrial antioxidants), and explore personalized clinical trials based on redox stratification. Overall, OS is a central mediator in vascular pathology, and progress in biomarker validation and targeted therapies will be essential to translate current knowledge into effective prevention, diagnosis, and treatment of cardiovascular diseases. Personalized approaches based on accurate redox profiling may enhance efficacy.
- 21 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 1075
Top Cited PapersOpen AccessOxidative Stress and Its Role in Vascular Damage and Atherosclerosis
Oxidative stress (OS) resulting from an imbalance between reactive oxygen species (ROS) generation and antioxidant defenses plays a pivotal role in vascular diseases such as atherosclerosis and hypertension. ROS derived from NADPH oxidase, mitochondria, and xanthine oxidase promote endothelial dysfunction by inducing lipid and protein oxidation, apoptosis, and pro-inflammatory signaling, thereby enhancing smooth muscle proliferation and atherogenesis. This review summarizes the molecular mechanisms linking OS to vascular injury and aims to systematically elucidate the role of OS in vascular diseases, with a specific focus on critiquing the current challenges in translating biomarkers to clinical practice and the emerging trends in personalized antioxidant therapy. Particular attention is given to biomarkers of oxidative stress, including those assessing antioxidant enzyme activity and oxidative damage products, which possess potential for clinical use. Therapeutic strategies targeting OS, including dietary and pharmacological antioxidants, show promise in improving vascular health, although clinical outcomes have been inconsistent and it is necessary to resolve the standardization and validation of these biomarkers, develop precise targeted therapies against specific ROS sources (e.g., NOX inhibitors, mitochondrial antioxidants), and explore personalized clinical trials based on redox stratification. Overall, OS is a central mediator in vascular pathology, and progress in biomarker validation and targeted therapies will be essential to translate current knowledge into effective prevention, diagnosis, and treatment of cardiovascular diseases. Personalized approaches based on accurate redox profiling may enhance efficacy.
- Open Access
- 22 September 2025
- Published by MDPI AG in Preprints.org
Oxidative Stress and Its Role in Vascular Damage and Atherosclerosis
Oxidative stress (OS), resulting from an imbalance between reactive oxygen species (ROS) generation and antioxidant defenses, plays a pivotal role in vascular diseases such as atherosclerosis and hypertension. ROS derived from NADPH oxidase, mitochondria, and xanthine oxidase promote endothelial dysfunction by inducing lipid and protein oxidation, apoptosis, and pro-inflammatory signaling, thereby enhancing smooth muscle proliferation and atherogenesis. This review summarizes the molecular mechanisms linking OS to vascular injury and highlights the interplay between ROS and inflammation in the progression of cardiovascular disease. Particular attention is given to biomarkers of oxidative stress, including those assessing antioxidant enzyme activity and oxidative damage products, which hold potential for clinical use. However, challenges remain regarding their standardization and variability influenced by biological and environmental factors. Therapeutic strategies targeting OS, including dietary and pharmacological antioxidants, show promise in improving vascular health, although clinical outcomes have been inconsistent. Personalized approaches based on accurate redox profiling may enhance efficacy. Overall, OS is a central mediator in vascular pathology, and progress in biomarker validation and targeted therapies will be essential to translate current knowledge into effective prevention, diagnosis, and treatment of cardiovascular diseases.
- 22 September 2025
- Published by MDPI AG in Preprints.org
Open AccessOxidative Stress and Its Role in Vascular Damage and Atherosclerosis
Oxidative stress (OS), resulting from an imbalance between reactive oxygen species (ROS) generation and antioxidant defenses, plays a pivotal role in vascular diseases such as atherosclerosis and hypertension. ROS derived from NADPH oxidase, mitochondria, and xanthine oxidase promote endothelial dysfunction by inducing lipid and protein oxidation, apoptosis, and pro-inflammatory signaling, thereby enhancing smooth muscle proliferation and atherogenesis. This review summarizes the molecular mechanisms linking OS to vascular injury and highlights the interplay between ROS and inflammation in the progression of cardiovascular disease. Particular attention is given to biomarkers of oxidative stress, including those assessing antioxidant enzyme activity and oxidative damage products, which hold potential for clinical use. However, challenges remain regarding their standardization and variability influenced by biological and environmental factors. Therapeutic strategies targeting OS, including dietary and pharmacological antioxidants, show promise in improving vascular health, although clinical outcomes have been inconsistent. Personalized approaches based on accurate redox profiling may enhance efficacy. Overall, OS is a central mediator in vascular pathology, and progress in biomarker validation and targeted therapies will be essential to translate current knowledge into effective prevention, diagnosis, and treatment of cardiovascular diseases.